Trade

with

AcelRx Pharmaceuticals Inc
(NASDAQ: ACRX)
AdChoices
6.61
-0.24
-3.50%
After Hours :
6.61
0.00
0.00%

Open

6.95

Previous Close

6.85

Volume (Avg)

257.23k (1.10M)

Day's Range

6.59-6.95

52Wk Range

5.22-13.64

Market Cap.

297.13M

Dividend Rate ( Yield )

-

Beta

2.16

Shares Outstanding

43.38M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Medical Devices
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 29.50M

    • Net Income

    • -23.43M

    • Market Cap.

    • 297.13M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -47.40

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.16

    • Forward P/E

    • -5.79

    • Price/Sales

    • 10.41

    • Price/Book Value

    • 5.35

    • Price/Cash flow

    • -222.22

      • EBITDA

      • -21.32M

      • Return on Capital %

      • -19.02

      • Return on Equity %

      • -43.59

      • Return on Assets %

      • -19.02

      • Book Value/Share

      • 1.28

      • Shares Outstanding

      • 43.38M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 8.67

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -1.45

        • Cashflow Estimate

        • 0.33

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -82.60

          • 2.66

          • Net Income

            YTD/YTD (last year)

          • -

          • -22.64

          • Net Income

            Q/Q (last year)

          • -

          • -29.83

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 4.60

          • Net Income

            5-Year Annual Average

          • -

          • -1.34

          • Dividends

            5-Year Annual Average

          • -

          • -0.25

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 64.08

            • Pre-Tax Margin

            • -47.40

            • 15.19

            • Net Profit Margin

            • -47.40

            • 13.09

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 65.03

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 17.99

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 191.75B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.40

              • 0.34

              • Current Ratio

              • 10.67

              • 2.55

              • Quick Ratio

              • 10.57

              • 1.83

              • Interest Coverage

              • -7.07

              • 11.70

              • Leverage Ratio

              • 1.81

              • 1.86

              • Book Value/Share

              • 1.28

              • 11.69

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -21.83

                • 34.01

                • P/E Ratio 5-Year High

                • -43.47

                • 224.03

                • P/E Ratio 5-Year Low

                • -5.61

                • 60.23

                • Price/Sales Ratio

                • 10.41

                • 3.17

                • Price/Book Value

                • 5.35

                • 3.20

                • Price/Cash Flow Ratio

                • -222.22

                • 18.42

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -43.59

                        (-)

                      • 12.33

                        (18.16)

                      • Return on Assets %

                        (5-Year Average)

                      • -19.02

                        (-83.50)

                      • 6.62

                        (8.69)

                      • Return on Capital %

                        (5-Year Average)

                      • -23.85

                        (-)

                      • 8.49

                        (11.48)

                      • Income/Employee

                      • -

                      • 34.11k

                      • Inventory Turnover

                      • -

                      • 2.77

                      • Asset Turnover

                      • 0.40

                      • 0.51

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -6.67M
                      Operating Margin
                      -22.60
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -222.22
                      Ownership

                      Institutional Ownership

                      85.75%

                      Top 10 Institutions

                      62.07%

                      Mutual Fund Ownership

                      15.88%

                      Float

                      61.58%

                      5% / Insider Ownership

                      2.31%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        610,629

                      • 0.00

                      • 1.41

                      • iShares Nasdaq Biotechnology

                      •  

                        575,815

                      • -0.69

                      • 1.67

                      • Vanguard Total Stock Mkt Idx

                      •  

                        453,032

                      • 0.00

                      • 1.04

                      • Vanguard VIF Small Comp Gr

                      •  

                        450,030

                      • 0.00

                      • 1.04

                      • iShares Russell 2000 (AU)

                      •  

                        390,041

                      • -1.01

                      • 1.13

                      • Oppenheimer Main Street Small Cap VA

                      •  

                        389,860

                      • 0.00

                      • 0.90

                      • Vanguard US Discoveries Fund

                      •  

                        266,105

                      • -5.37

                      • 0.61

                      • Vanguard Extended Market Index Fund

                      •  

                        243,054

                      • 22.72

                      • 0.56

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Perceptive Advisors LLC

                      •  

                        6,574,060

                      • 0.00%

                      • 15.16

                      • Three Arch Management IV LLC

                      •  

                        5,839,722

                      • +44.32%

                      • 13.48

                      • Three Arch Management III LLC

                      •  

                        3,527,319

                      • -9.65%

                      • 8.14

                      • Skyline Venture Management IV LLC

                      •  

                        2,851,933

                      • -31.64%

                      • 6.58

                      • Granahan Investment Management Inc..

                      •  

                        1,559,623

                      • +74.84%

                      • 3.60

                      • BlackRock Fund Advisors

                      •  

                        1,115,876

                      • -5.05%

                      • 2.57

                      • Driehaus Capital Management LLC

                      •  

                        1,115,183

                      • -39.08%

                      • 2.57

                      • Franklin Advisers, Inc.

                      •  

                        964,800

                      • 0.00%

                      • 2.22

                      • Foresite Capital Management I, LLC

                      •  

                        847,983

                      • -38.51%

                      • 1.96

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Medical Devices

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialt...morey pharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. The Company’s main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe ...moreand Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.lessless

                      Key People

                      Mr. Richard A. King

                      CEO/Director/President

                      Mr. Adrian Adams

                      Director/Chairman of the Board

                      Dr. Pamela P. Palmer

                      Chief Medical Officer/Co-Founder/Director

                      Timothy E. Morris

                      CFO/Chief Accounting Officer

                      Mark A. Wan

                      Director

                      • AcelRx Pharmaceuticals Inc

                      • 351 Galveston Drive

                      • Redwood City, CA 94063

                      • USA.Map

                      • Phone: +1 650 216-3500

                      • Fax: +1 650 216-6500

                      • acelrx.com

                      Incorporated

                      2005

                      Employees

                      44

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: